News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fibrocell Science, Inc. Announces Exclusive Technology License Agreements With University of California, Los Angeles (UCLA) To Advance The Development Of Personalized Cell Therapies


6/17/2014 10:03:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced today that it has entered into an exclusive license agreement with The Regents of the University of California. Under the agreement, Fibrocell acquired the rights to commercially apply patented discoveries and technologies resulting from the ongoing scientific collaboration between the University of California at Los Angeles (UCLA) and Fibrocell Science.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES